Suppr超能文献

二十七例肾移植后临床操作性耐受的自然史。

The natural history of clinical operational tolerance after kidney transplantation through twenty-seven cases.

机构信息

Institut National de la Sante Et de la Recherche Medicale INSERM U643, and Institut de Transplantation Urologie Néphrologie du Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France.

出版信息

Am J Transplant. 2012 Dec;12(12):3296-307. doi: 10.1111/j.1600-6143.2012.04249.x. Epub 2012 Sep 13.

Abstract

We report here on a European cohort of 27 kidney transplant recipients displaying operational tolerance, compared to two cohorts of matched kidney transplant recipients under immunosuppression and patients who stopped immunosuppressive drugs and presented with rejection. We report that a lower proportion of operationally tolerant patients received induction therapy (52% without induction therapy vs. 78.3%[p = 0.0455] and 96.7%[p = 0.0001], respectively), a difference likely due to the higher proportion (18.5%) of HLA matched recipients in the tolerant cohort. These patients were also significantly older at the time of transplantation (p = 0.0211) and immunosuppression withdrawal (p = 0.0002) than recipients who rejected their graft after weaning. Finally, these patients were at lower risk of infectious disease. Among the 27 patients defined as operationally tolerant at the time of inclusion, 19 still display stable graft function (mean 9 ± 4 years after transplantation) whereas 30% presented slow deterioration of graft function. Six of these patients tested positive for pre-graft anti-HLA antibodies. Biopsy histology studies revealed an active immunologically driven mechanism for half of them, associated with DSA in the absence of C4d. This study suggests that operational tolerance can persist as a robust phenomenon, although eventual graft loss does occur in some patients, particularly in the setting of donor-specific alloantibody.

摘要

我们在此报告了 27 例在欧洲接受肾移植并表现出免疫耐受的患者,与接受免疫抑制治疗的 2 例匹配的肾移植患者和停止免疫抑制药物治疗并出现排斥反应的患者进行了比较。我们报告说,较低比例的免疫耐受患者接受了诱导治疗(52%未接受诱导治疗,分别与 78.3%[p=0.0455]和 96.7%[p=0.0001]相比),这一差异可能是由于耐受组中 HLA 匹配受者的比例较高(18.5%)。这些患者在移植时(p=0.0211)和停药时(p=0.0002)也明显比那些在停药后排斥移植物的患者年龄更大。最后,这些患者感染疾病的风险较低。在纳入时被定义为免疫耐受的 27 例患者中,有 19 例仍显示稳定的移植物功能(移植后平均 9±4 年),而 30%的患者移植物功能出现缓慢恶化。其中 6 例患者的移植前抗 HLA 抗体检测呈阳性。活检组织学研究显示,其中一半患者存在活跃的免疫驱动机制,与缺乏 C4d 的 DSA 相关。这项研究表明,尽管最终一些患者确实会发生移植物丢失,特别是在存在供体特异性同种抗体的情况下,免疫耐受仍然可以作为一种强大的现象持续存在。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验